Finally, the development of novel FXS models—such as the FMR1 KO rat (Till et al., 2015; Golden et al., 2019; Auerbach et al., 2021) and FXS human derived iPS cells (Telias et al., 2013; Bhattacharyya and Zhao, 2016) and organoids (Kang et al., 2021), will help identify which phenotypes are most highly conserved across species and highlight new treatment strategies. This evidence concerns the gene FMR1 and fragile X syndrome.